Practical guide to palliative sedation.

Area of Science:

• Palliative Care
• End-of-Life Symptom Management

Background:

• Terminally ill patients prioritize symptom control during the dying process.
• Standard palliative care manages most end-of-life symptoms effectively.
• Refractory symptoms like pain, dyspnea, nausea, and delirium can persist despite standard care.

Purpose of the Study:

• To explore palliative sedation (PS) as a therapeutic option for refractory symptoms in terminally ill patients.
• To address concerns regarding the impact of PS on patient survival.
• To differentiate PS from euthanasia.

Main Methods:

• Review of existing data on the use and outcomes of palliative sedation.
• Analysis of reported frequencies of PS application in terminally ill populations.
• Examination of the temporal relationship between PS initiation and patient death.

Main Results:

• Palliative sedation is utilized in 5% to 52% of terminally ill patients.
• Initiating palliative sedation does not appear to cause immediate death.
• The median survival time after starting PS is reported to be between 1 to 5 days.
• Midazolam is frequently used for palliative sedation.

Conclusions:

• Palliative sedation is a viable option for managing intractable symptoms at the end of life.
• The primary intent of palliative sedation is symptom relief, not hastening death.
• Palliative sedation is ethically and clinically distinct from euthanasia.